Andrew M Fukuda1, Lauren E Hindley1, Jee Won Diane Kang1, Eric Tirrell1, Audrey R Tyrka1,2,3,4, Alfred Ayala4, Linda L Carpenter1,2,3,4. 1. Butler Hospital TMS Clinic and Neuromodulation Research Facility. 2. Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University. 3. Mood Disorders Research Program and Laboratory for Clinical and Translational Neuroscience, Butler Hospital. 4. Division of Surgical Research/Department of Surgery, Rhode Island Hospital/Brown University School of Medicine, Providence, Rhode Island, USA.
Abstract
OBJECTIVES: To determine if vascular endothelial growth factor (VEGF) changes with transcranial magnetic stimulation (TMS) in treatment-resistant major depressive disorder (MDD). METHODS: Serum from a naturalistic population of 15 patients with MDD was collected at baseline and after standard TMS treatment. VEGF concentration was determined via ELISA. Inventory of Depressive Symptomatology Self Report and Patient Health Questionnaire were used as a measure of depression symptom severity, clinical response and remission. Mann-Whitney U and Kendall's Tau Correlation were used for continuous variables. RESULTS: VEGF increased from pre- to post-TMS (+30.3%) in remitters whereas VEGF decreased in non-remitters (-9.87%) (P < 0.05). This same pattern was observed when comparing mean %change in VEGF between responders (+14.7%) and non-responders (-14.9%) (P = 0.054). Correlation was present between change in VEGF concentration (baseline to post) and change in Inventory of Depressive Symptomatology-Self Report at Tx30 (r = -0.371, P < 0.054), reflecting greater increases in VEGF linked to greater improvement in depressive symptoms following the standard 6-week course of TMS. CONCLUSION: Patients with a successful treatment with TMS had significantly greater increase in VEGF from baseline to after treatment compared to non-responders/non-remitters and a larger increase in VEGF was associated with greater improvement in depressive symptoms after TMS. This is the first report examining VEGF levels in depressed patients receiving TMS. This study provides correlative data supporting further investigation into VEGF's role as an important mediator in the processes underpinning TMS' antidepressant effects and as a potential biomarker of clinical outcomes.
OBJECTIVES: To determine if vascular endothelial growth factor (VEGF) changes with transcranial magnetic stimulation (TMS) in treatment-resistant major depressive disorder (MDD). METHODS: Serum from a naturalistic population of 15 patients with MDD was collected at baseline and after standard TMS treatment. VEGF concentration was determined via ELISA. Inventory of Depressive Symptomatology Self Report and Patient Health Questionnaire were used as a measure of depression symptom severity, clinical response and remission. Mann-Whitney U and Kendall's Tau Correlation were used for continuous variables. RESULTS: VEGF increased from pre- to post-TMS (+30.3%) in remitters whereas VEGF decreased in non-remitters (-9.87%) (P < 0.05). This same pattern was observed when comparing mean %change in VEGF between responders (+14.7%) and non-responders (-14.9%) (P = 0.054). Correlation was present between change in VEGF concentration (baseline to post) and change in Inventory of Depressive Symptomatology-Self Report at Tx30 (r = -0.371, P < 0.054), reflecting greater increases in VEGF linked to greater improvement in depressive symptoms following the standard 6-week course of TMS. CONCLUSION: Patients with a successful treatment with TMS had significantly greater increase in VEGF from baseline to after treatment compared to non-responders/non-remitters and a larger increase in VEGF was associated with greater improvement in depressive symptoms after TMS. This is the first report examining VEGF levels in depressed patients receiving TMS. This study provides correlative data supporting further investigation into VEGF's role as an important mediator in the processes underpinning TMS' antidepressant effects and as a potential biomarker of clinical outcomes.
Authors: Jerome A Yesavage; J Kaci Fairchild; Zhibao Mi; Kousick Biswas; Anne Davis-Karim; Ciaran S Phibbs; Steven D Forman; Michael Thase; Leanne M Williams; Amit Etkin; Ruth O'Hara; Gerald Georgette; Tamara Beale; Grant D Huang; Art Noda; Mark S George Journal: JAMA Psychiatry Date: 2018-09-01 Impact factor: 21.596
Authors: A Minelli; E Maffioletti; M Bortolomasi; A Conca; R Zanardini; L Rillosi; M Abate; M Giacopuzzi; G Maina; M Gennarelli; L Bocchio-Chiavetto Journal: Acta Psychiatr Scand Date: 2013-08-20 Impact factor: 6.392
Authors: David L Dunner; Scott T Aaronson; Harold A Sackeim; Philip G Janicak; Linda L Carpenter; Terrence Boyadjis; David G Brock; Dafna Bonneh-Barkay; Ian A Cook; Karl Lanocha; H Brent Solvason; Mark A Demitrack Journal: J Clin Psychiatry Date: 2014-12 Impact factor: 4.384
Authors: L A Carvalho; J P Torre; A S Papadopoulos; L Poon; M F Juruena; K Markopoulou; A J Cleare; C M Pariante Journal: J Affect Disord Date: 2012-11-27 Impact factor: 4.839
Authors: André F Carvalho; Cristiano A Köhler; Roger S McIntyre; Christian Knöchel; André R Brunoni; Michael E Thase; João Quevedo; Brisa S Fernandes; Michael Berk Journal: Psychoneuroendocrinology Date: 2015-07-08 Impact factor: 4.905
Authors: Alice Pisoni; Rebecca Strawbridge; John Hodsoll; Timothy R Powell; Gerome Breen; Stephani Hatch; Matthew Hotopf; Allan H Young; Anthony J Cleare Journal: Front Psychiatry Date: 2018-08-23 Impact factor: 4.157
Authors: Madhukar H Trivedi; Amit Etkin; Wei Wu; Yu Zhang; Jing Jiang; Molly V Lucas; Gregory A Fonzo; Camarin E Rolle; Crystal Cooper; Cherise Chin-Fatt; Noralie Krepel; Carena A Cornelssen; Rachael Wright; Russell T Toll; Hersh M Trivedi; Karen Monuszko; Trevor L Caudle; Kamron Sarhadi; Manish K Jha; Joseph M Trombello; Thilo Deckersbach; Phil Adams; Patrick J McGrath; Myrna M Weissman; Maurizio Fava; Diego A Pizzagalli; Martijn Arns Journal: Nat Biotechnol Date: 2020-02-10 Impact factor: 54.908